Author:
Lamarca Angela,Ostios Lorena,McNamara Mairéad G.,Garzon Carlos,Gleeson Jack P.,Edeline Julien,Herrero Ana,Hubner Richard A.,Moreno Victor,Valle Juan W.
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference94 articles.
1. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2022
2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer - PubMed [Internet]. [cited 2022 Feb 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/20375404/.
3. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial;Lamarca;Lancet Oncol,2021
4. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol [Internet]. [cited 2021 Nov 22]. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00486-1/fulltext.
5. Yoo C. Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC) [Internet]. Ann Oncol 2022;33(suppl_7):S19–26. doi: 10.1016/annonc/annonc1036.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献